ɬŔď·¬

Journal News

New mass spectrometry tool accurately identifies bacteria

Ecem Arpaci
By Ecem Arpaci
April 30, 2025

Scientists identify bacterial species by analyzing their proteins using mass spectrometry, or MS. This technique first fragments proteins into smaller peptides using an enzyme called trypsin. These sequences can then be compared to references in databases. The largest MS-based studies on bacteria have focused on just a handful of species, so a team of researchers recently created a resource for mapping data onto a more diverse population of bacteria.

Miriam Abele, Armin Soleymaniniya and colleagues at the Technical University of Munich developed MS2Bac, a software system that enables bacterial identification from protein data. They published their in Molecular & Cellular Proteomics. MS2Bac maps tryptic peptides onto reference bacterial species or strains, achieving almost perfect accuracy for species identification. To develop this tool, the team first performed MS on the proteins from over 300 bacterial species to create a reference database. They also compared their identification method with other approaches, such as Fourier transform infrared spectroscopy, and found that MS2Bac was the most accurate.

MS2Bac can also identify specific proteins, antibiotic resistance markers. It covers many hypothetical proteins, which are not well understood, providing a basis for further functional studies. This is the first study to incorporate single-cell organisms into the database, a proteomics resource for multiomics analyses. This tool will greatly help researchers and clinicians determine bacterial species from clinically and environmentally relevant samples.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ecem Arpaci
Ecem Arpaci

Ecem Arpaci is a biochemistry student at Imperial College London and a research intern at Radboud University Medical Center. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Teaching AI to listen
Essay

Teaching AI to listen

Sept. 18, 2025

A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Journal News

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder

Sept. 16, 2025

Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Journal News

How sugars shape Marfan syndrome

Sept. 10, 2025

Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.